OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma
Source: Targeted Oncology, April 2024
Intravenous infusion with OBX-115, an IL-2–free, regulatable, engineered tumor-infiltrating lymphocyte (TIL) cell therapy was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma, according to data from a first-in-human, single-center, phase 1 study (NCT05470283) presented at the 2024 AACR Annual Meeting.
The results demonstrated that the investigator-assessed objective response rate (ORR) was 50% among evaluable patients (n = 6), which included 2 complete responses, 1 partial response (PR), and 3 cases of stable disease for a disease control rate of 100%. Additionally, all patients were alive at the January 2, 2024, data cut-off. Notably, despite ongoing tumor growth in most patients prior to OBX-115 infusion, all patients experienced reductions in tumor burden and meaningful disease control for at least 12 weeks following treatment.
Furthermore, durable responses occurred, particularly in cases where OBX-115 was manufactured from core needle biopsy (CNB) tumor tissue. Additionally, the median progression-free survival (PFS) was not reached with a median follow-up of 24.9 weeks (range, 15.7-56.0).